Skip to main content
SpringerLink
Log in

Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma

  • Chapter
  • First Online:
Methods of Cancer Diagnosis, Therapy, and Prognosis

Part of the book series: Methods of Cancer Diagnosis, Therapy and Prognosis ((HAYAT,volume 6))

  • 1636 Accesses

Abstract

Multiple myeloma (MM) is the second most common hematologic B-cell malignancy, affecting > 16,000 individuals each year in the United States with a median life expectancy of 3–5 years and a prevalence accounting for ∼50,000 patients alive annually, and contributing to ∼12,000 cancer related deaths. MM is characterized by accumulation of clonal malignant plasma cells predominantly within the bone marrow and a heterogenous clinical course, which can be often preceded by a premalignant condition, defined as monoclonal gammopathy of undetermined significance (MGUS), and may progress to extramedullary and/or disseminated disease. MM is associated with a constellation of disease manifestations, including osteolytic lesions due to uncoupled bone metabolism, anemia and immunosuppression due to loss of normal hematopoietic stem cell function, and end-organ damage due to monoclonal immunoglobulin secretion (Barlogie et al. 2004).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adamietz, I.A., Schober, C., and Schulte RW.M. (1991) Palliative radiotherapy in plasma cell myeloma. Radiother. Oncol. 20:111–116

    Article  PubMed  CAS  Google Scholar 

  • Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., and Crowley, J. (2004) Treatment of multiple myeloma. Blood 103:20–32

    Article  PubMed  CAS  Google Scholar 

  • Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., and Klein, B. (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86:685–691

    PubMed  CAS  Google Scholar 

  • Bosch, A., and Frias, Z. (1988) Radiotherapy in the treatment of multiple myeloma. Int. J. Rad. Oncol. Biol. Phys. 15:1363–1369

    Article  CAS  Google Scholar 

  • Carlo-Stella, C., Guidetti, A., Nicola, M.D., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F., and Gianni, A.M. (2007) IFN-γ enhances the antimyeloma activity of the fully human anti–human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer. Res. 67:3269–3675

    Article  PubMed  CAS  Google Scholar 

  • Chanan-Khan, A.A., Jagannath, S., Schlossman, R.L., Fram, R.J., Falzone, R.M., Ruberti, M.F., Welch, S.K., DePaolo, D., Anderson, K.C., and Munshi, N.C. (2006) Phase I study of BB-10901 (huN901-DM1) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. Blood 108: [abstract #3574]

    Google Scholar 

  • Chatterjee, M., Chakraborty, T., and Tassone, P. (2006) Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies., and targeted radiotherapy. Eur. J. Cancer. 42:1640–1652

    Article  PubMed  CAS  Google Scholar 

  • Christoforidou, A.V., Saliba, R.M., Williams, P., Qazilbash, M., Roden, L., Aleman, A., Weber, D., Mendoza, F., Podoloff, D., Wendt, R., Breitz, H., Alexanian, R., Champlin, R., and Giralt, S. (2007) Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166) Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol. Blood. Marrow. Transplant. 13:543–549

    Article  PubMed  Google Scholar 

  • Cohen, B.D., Baker, D.A., Soderstrom, C., Tkalcevic, G., Rossi, A.M., Miller, P.E., Tengowski, M.W., Wang, F., Gualberto, A., Beebe, J.S., and Moyer, J.D. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer. Res. 11:2063–2073

    Article  PubMed  CAS  Google Scholar 

  • Dispenzieri, A., Wiseman, G.A., Lacy, M.Q., Litzow, M.R., Anderson, P.M., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef IN.M., Ansell, S.M., Porrata, L., Elliott, M.A., Lust, J.A., Greipp, P.R., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Erlichman, C., Sloan, J.A., and Gertz, M.A. (2005) A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19:118–125

    PubMed  CAS  Google Scholar 

  • Francisco, J.A., Gawlak, S.L., and Siegall, C.B. (1997) Construction, expression, and characterization of BD1–G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin. J. Biol. Chem. 272:24165–24169

    Article  PubMed  CAS  Google Scholar 

  • Giles, F.J., McSweeney, E.N., Richards JD.M., Tobias, J.S., Gaminara, E.J., Grant, I.R., Kearney, J.W., Newland, A.C., Parker, N.E., and Schey, S. (1992) Prospective randomised study of double hemibody irradiation with., and without subsequent. maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur. J. Cancer. 28A:1392–1395

    Article  PubMed  CAS  Google Scholar 

  • Giralt, S., Bensinger, W., Goodman, M., Podoloff, D., Eary, J., Wendt, R., Alexanian, R., Weber, D., Maloney, D., Holmberg, L., Rajandran, J., Breitz, H., Ghalie, R., and Champlin, R. (2003) 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102:2684–2691

    Article  PubMed  CAS  Google Scholar 

  • Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dörken, B., and Bargou, R.C. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int. J. Cancer. 93:674–680

    Article  PubMed  CAS  Google Scholar 

  • Iuliano, F., Abruzzese, E., Molica, S., Peta, A., Toraldo, A., Levato, L., Piro, E., Palermo, S., and Ospedaliera, A. (2003) Samarium(Sm)153 ethylene diamine tetramethylene phosphonate (153Sm-EDTMP) targeted radiotherapy., and zoledronic acid. is an effective option for elderly with symptomatic refractory multiple myeloma. Blood 102: [ASH abstract #1630]

    Google Scholar 

  • Kumar, S., and Rajkumar, S.V. (2006) Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer. 42:1612–1622

    Article  PubMed  CAS  Google Scholar 

  • Lecouvet, F., Richard, F., Berg, B.V., Malghem, J., Maldague, B., Jamart, J., Ferrant, A., and Michaux, J.L. (1997) Long-term effects of localized spinal radiation therapy on vertebral fractures., and focal lesions. appearance in patients with multiple myeloma. Br. J. Haematol. 96:743–745

    Article  PubMed  CAS  Google Scholar 

  • Lewington VJ (2005) Bone-seeking radionuclides for therapy. J. Nucl. Med. 46:38S–47S

    PubMed  CAS  Google Scholar 

  • Lu, Z.Y., Brailly, H., Wijdenes, J., Bataille, R., Rossi, J.F., and Klein, B. (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86:3123–3131

    PubMed  CAS  Google Scholar 

  • Menu, E., Jernberg-Wiklund, H., Stromberg, T., De Raeve, H., Girnita, L., Larsson, O., Axelson, M., Asosingh, K., Nilsson, K., Van, C.B., and Vanderkerken, K. (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro. and in vivo. study in the 5T33MM mouse model. Blood 107:655–660

    Article  PubMed  CAS  Google Scholar 

  • Moreau, P., Harousseau, J.L., Wijdenes, J., Morineau, N., Milpied, N., and Bataille, R. (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol. 109:661–664

    Article  PubMed  CAS  Google Scholar 

  • Moreau, P., Facon, T., Attal, M., Hulin, C., Michallet, M., Maloisel, F., Sotto, J.J., Guilhot, F., Marit, G., Doyen, C., Jaubert, J., Fuzibet, J.G., François, S., Benboubker, L., Monconduit, M., Voillat, L., Macro, M., Berthou, C., Dorvaux, V., Pignon, B., Rio, B., Matthes, T., Casassus, P., Caillot, D., NajmanN, Grosbois, B., Bataille, R., and Harousseau, J.L. (2002) For the Intergroupe Francophone du Myélome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99: 731–735

    Google Scholar 

  • Moreau, P., Hullin, C., Garban, F., Yakoub-Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.J., Bataille, R., and Harousseau, J.L. (2006) For the Intergroupe Francophone du Myélome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective. and randomized IF.M. 99-04 protocol. Blood 107:397–403

    Article  PubMed  CAS  Google Scholar 

  • Multiple Myeloma Research Foundation. Available from URLs. www.multiplemyeloma.org; http://www.multiplemyeloma.org/treatments/3.08.13.php. Accessed on 08 May 2007

  • Olson, D.L., Burkly, L.C., Leone, D.R., Dolinski, B.M., and Roy, R.L. (2005) Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer. Ther. 4:91–99

    PubMed  CAS  Google Scholar 

  • Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N.C., Stirling, D.I., Antin, J.H., and Anderson, K.C. (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104:4188–4193

    Article  PubMed  CAS  Google Scholar 

  • Rossi, J.F., Fegueux, N., Lu, Z.Y., Legouffe, E., Exbrayat, C., Bozonnat, M.C., Navarro, R., Lopez, E., Quittet, P., Daures, J.P., Rouillé V, Kanouni, T., Widjenes, J., and Klein, B. (2005) Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone. Marrow. Transplant. 36:771–779

    Article  PubMed  CAS  Google Scholar 

  • Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S.V., Cardillo, T.M., Hansen, H.J., Horak, I.D., Griffiths, G.L., and Goldenberg, D.M. (2005) Anti-CD74 antibody-doxorubicin conjugate., IMMU-110, in a human multiple myeloma xenograft., and in monkeys. Clin. Cancer. Res. 11:5257–5264

    Article  PubMed  CAS  Google Scholar 

  • Supiot, S., Faivre-Chauvet, A., Couturier, O., Heymann, M.F., Robillard, N., Kraeber-Bodéré F, Morandeau, L., Mahé MA, Chérel M (2002) Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 94:1202–1219

    Article  PubMed  CAS  Google Scholar 

  • Supiot, S., Gouard, S., Charrier, J., Apostolidis, C., Chatal, J.F., Barbet, J., Davodeau, F., and Cherel, M. (2005) Mechanisms of cell sensitization to α-radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin. Cancer. Res. 11:7047s–7052s

    Article  PubMed  CAS  Google Scholar 

  • Tai, Y.T., Catley, L.P., Mitsiades, C.S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P., Treon, S.P., Munshi, N.C., and Anderson, K.C. (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer. Res. 64:2846–2852

    Article  PubMed  CAS  Google Scholar 

  • Tai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M., and Anderson, K.C. (2005) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer. Res. 65:5898–5906

    Article  PubMed  CAS  Google Scholar 

  • Tassone, P., Galea, E., Forciniti, S., Tagliaferri, P., and Venuta, S. (2002) The IL-6 receptor super-antagonist Sant7 enhances antiproliferative. and apoptotic effects. induced by dexamethasone., and zoledronic acid. on multiple myeloma cells. Int. J. Oncol. 21:867–873

    PubMed  CAS  Google Scholar 

  • Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C., and Anderson, K.C. (2004a) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688–3696

    Article  PubMed  CAS  Google Scholar 

  • Tassone, P., Gozzini, A., Goldmacher, V.S., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C., and Munshi, N.C. (2004b) In vitro. and in vivo. activity of the maytansinoid immunoconjugate huN901–N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ multiple myeloma cells. Cancer. Res. 64:4629–4636

    Article  PubMed  CAS  Google Scholar 

  • Tassone, P., Neri, P., Burger, R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C., and Munshi, N.C. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer. Res. 11:4251–4258

    Article  PubMed  CAS  Google Scholar 

  • Trikha, M., Corringham, R., Klein, B., and Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale. and clinical evidence. Clin. Cancer. Res. 9:4653–4665

    PubMed  CAS  Google Scholar 

  • van Zaanen HC.T., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., van der Lelie, J., van Oers MH (1998) Chimeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Hematol 102:783–790

    Article  Google Scholar 

  • Yasui, H., Hideshima, T., Raje, N., Roccaro, A.M., Shiraishi, N., Kumar, S., Hamasaki, M., Ishitsuka, K., Tai, Y.T., Podar, K., Catley, L., Mitsiades, C.S., Richardson, P.G., Albert, R., Brinkmann, V., Chauhan, D., and Anderson, K.C. (2005) FTY720 induces apoptosis in multiple myeloma cells. and overcomes drug. resistance. Cancer. Res. 65:7478–7484

    Article  PubMed  CAS  Google Scholar 

  • Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T., and Nishimoto, N. (2007) Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer. Res. 67:871–875

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Biochemistry, Department of Pharmaceutical Technology, Jadavpur University, 17028, Calcutta, 700032, West Bengal, India

    Malay Chatterjee, Tridib Chakraborty & Ajay Rana

Authors
  1. Malay Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rangasamy Manivannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amalendu Pande
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tridib Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ajay Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Biological Sciences, Kean University, Union, 07083, U.S.A.

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Chatterjee, M., Manivannan, R., Pande, A., Chakraborty, T., Rana, A. (2010). Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma. In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2918-8_30

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-2918-8_30

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-2917-1

  • Online ISBN: 978-90-481-2918-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation